Edition:
United States

Arno Therapeutics Inc (ARNI.PK)

ARNI.PK on OTC Markets Group

0.11USD
24 Mar 2017
Change (% chg)

-- (--)
Prev Close
$0.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
40,583
52-wk High
$0.92
52-wk Low
$0.05

Latest Key Developments (Source: Significant Developments)

Arno Therapeutics reports Q1 adj loss of $0.05 per share
Monday, 16 May 2016 05:05pm EDT 

Arno Therapeutics Inc :Q1 adjusted non-gaap loss per share $0.05.  Full Article

Arno Therapeutics Inc announces resignation of chief operating officer and chief financial officer - Form 8-K
Friday, 11 Sep 2015 04:32pm EDT 

Arno Therapeutics Inc:Says that on Sept. 4, Lawrence A. Kenyon, chief operating officer and chief financial officer of Arno Therapeutics Inc, provided written notice to the company that he is resigning his employment with the company, effective as of Sept. 15.  Full Article

Arno Therapeutics announces issuance of first Onapristone Patent
Thursday, 4 Jun 2015 08:30am EDT 

Arno Therapeutics Inc:Has been issued United States Patent Number 9,046,534 by the U.S. Patent and Trademark Office (USPTO).Patent related to the methods and systems for identifying and treating patients with anti-progestin sensitive tumors using the Company's lead product candidate, onapristone.  Full Article

Arno Therapeutics announces cooperative research and development agreement with U.S Army Medical Research Institute of Infectious Diseases
Wednesday, 3 Jun 2015 08:30am EDT 

Arno Therapeutics:Enters into a Cooperative Research and Development Agreement (CRADA) Material Transfer Agreement with the US Army Medical Research Institute of Infectious Diseases (USAMRIID).Agreement to evaluate the anti-viral activity of AR-12 and various analogues against Ebola and other viruses of biodefense interest.  Full Article

Arno Therapeutics Inc receives european orphan drug designation for AR-12 to reat two infectious diseases
Thursday, 30 Apr 2015 08:30am EDT 

Arno Therapeutics Inc:Says european commission, acting on recommendation from committee for orphan medicinal products (COMP) of European Medicines Agency (EMA), has designated AR-12 as an orphan medicinal product.For treatment of two separate infectious diseases, cryptococcosis and tularaemia.Says AR-12 orphan medicinal product designation was based on application packages that contained relevant data from pre-clinical models for each condition.In application regarding cryptococcosis, results of an animal model evaluating AR-12 showed reduction in brain fungal burden in combination with fluconazole, an antifungal medication.In application regarding tularaemia, results of an animal model evaluating AR-12 showed improved survival in combination with gentamicin.  Full Article

More From Around the Web

No consensus analysis data available.